Within-person prospective associations between depressive symptoms, abstinence self-efficacy and smoking cessation following smoking cessation treatment
Background: Abstinence self-efficacy and depressive symptoms have independently been associated with smoking outcomes in previous research. However, their bidirectional relationships with smoking abstinence over time remain underexplored. This study examined bidirectional and prospective association...
| Authors: | , , , , |
|---|---|
| Format: | article |
| Publication Date: | 2025 |
| Country: | España |
| Institution: | Universidad de Santiago de Compostela (USC) |
| Repository: | Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela |
| Language: | English |
| OAI Identifier: | oai:minerva.usc.gal:10347/46342 |
| Online Access: | https://hdl.handle.net/10347/46342 |
| Access Level: | Open access |
| Keyword: | Smoking abstinence Depressive symptoms Abstinence self-efficacy Longitudinal associations Random intercept cross-lagged panel model 12-month follow-up 320105 Psicología clínica |
| Summary: | Background: Abstinence self-efficacy and depressive symptoms have independently been associated with smoking outcomes in previous research. However, their bidirectional relationships with smoking abstinence over time remain underexplored. This study examined bidirectional and prospective associations between depressive symptoms, abstinence self-efficacy, and smoking abstinence from the end of a cognitive-behavioral smoking cessation intervention to 12-month follow-up. Methods: This study was conducted with 685 adults (62.04 % female; Mage=45.51) who sought smoking cessation treatment at the Smoking Cessation and Addictive Disorders Unit (University of Santiago de Compostela, Spain). Abstinence was defined as not smoking, not even a puff, in the prior 24 h at the end of the intervention and not smoking in the prior 7 days at each follow-up. A Random Intercept Cross-Lagged Panel Model was performed to examine the bidirectional and prospective associations between study variables. Results: At the within-person level, smoking abstinence at posttreatment and 3-month follow-up predicted greater abstinence self-efficacy and fewer depressive symptoms at 3- and 6-month follow-up, respectively. In contrast, higher abstinence self-efficacy at posttreatment was associated with lower odds of abstinence at 3-month follow-up, and abstinence self-efficacy at 3 months predicted more depressive symptoms at 6 months. Depressive symptoms did not significantly predict abstinence self-efficacy or smoking abstinence in the cross-lagged associations at any time point. Conclusion: Quitting smoking predicts higher abstinence self-efficacy and lower depressive symptoms after posttreatment, but these effects diminish after 6-month follow-up. Notably, higher levels of abstinence self-efficacy at the end of treatment may increase smoking risk during the first three months postquitting. |
|---|